Literature DB >> 17590244

WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006.

Morag Ferguson1, Ichiro Kurane, Omala Wimalaratne, Jinho Shin, David Wood.   

Abstract

The World Health Organization (WHO) publishes technical guidance on the quality, safety and efficacy of vaccines intended to assist national regulatory authorities and manufacturers. As part of its programme, WHO convened an informal consultation to initiate revision of the WHO recommendations on the production and control of inactivated Japanese encephalitis (JE) vaccines for human use, at its headquarters in June 2006. The attendees included experts from national regulatory authorities, national control laboratories and manufacturers from around the world as per WHO policy to include all relevant stakeholders in the standards development process. Issues pertaining to recent development with inactivated JE vaccines were presented and discussed. Participants agreed upon the scientific basis of revised specifications and the inclusion of new sections on nonclinical and clinical evaluation of inactivated JE vaccines. It was agreed that the revision would cover both existing vaccines derived from mouse brain or primary cell cultures and vaccines under development in a continuous cell line (Vero).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17590244     DOI: 10.1016/j.vaccine.2007.05.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Authors:  Shigefumi Okamoto; Hironori Yoshii; Masaaki Matsuura; Asato Kojima; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Michiaki Takahashi; Koichi Yamanishi; Yasuko Mori
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Authors:  Peter E Nasveld; Andrew Ebringer; Nathan Elmes; Sonya Bennett; Sutee Yoksan; John Aaskov; Karen McCarthy; Niranjan Kanesa-thasan; Claude Meric; Mark Reid
Journal:  Hum Vaccin       Date:  2010-12-01

3.  Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis.

Authors:  Jennifer L Uhrlaub; James D Brien; Douglas G Widman; Peter W Mason; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2011-02-21       Impact factor: 5.422

Review 4.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

5.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

6.  Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

Authors:  Sean T Duggan; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength.

Authors:  Ole Lund; Eduardo J M Nascimento; Milton Maciel; Morten Nielsen; Mette Voldby Larsen; Claus Lundegaard; Mikkel Harndahl; Kasper Lamberth; Søren Buus; Jérôme Salmon; Thomas J August; Ernesto T A Marques
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

8.  The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.

Authors:  Yuko Muraki; Takeshi Fujita; Masaaki Matsuura; Isao Fuke; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Kouichi Morita
Journal:  Virol J       Date:  2015-04-09       Impact factor: 4.099

9.  Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.

Authors:  Akira Higuchi; Hiroko Toriniwa; Tomoyoshi Komiya; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

10.  Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry.

Authors:  Jinliang Wang; Jie Yang; Jinying Ge; Ronghong Hua; Renqiang Liu; Xiaofeng Li; Xijun Wang; Yu Shao; Encheng Sun; Donglai Wu; Chengfeng Qin; Zhiyuan Wen; Zhigao Bu
Journal:  Virol J       Date:  2016-06-24       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.